← Leaderboards
Said M Sebti
University Of South Florida
$16,720,811
Attributed
$17,568,600
Total exposure
14
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.1M · FY2005–22$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$39,928,050 · 17
By mechanism
P01$15,446,317 · 4
U19$9,552,581 · 7
R01$8,738,862 · 5
R35$6,190,290 · 1
Top collaborators
- Nicholas James Lawrence5 shared
Most similar at University Of South Florida
Same institution · by research overlap
- Jeffrey P Krischer$693,386,575
- William S. Dalton$20,173,582
- Patricia J Emmanuel$10,113,266
- Paul B Jacobsen$11,373,914
- Warren Jackson Pledger$8,054,101
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsDesignApoptosisTumorProteinsInhibitor/AntagonistCancer TherapySignal TransductionProgramsAntineoplasticsLeadAthymic MouseAntineoplastic AgentsEnzyme InhibitorsMalignant - DescriptorBaseTumor GrowthAlkyltransferaseTumorigenesisNeoplasm MetastasisChemotherapyResistanceHigh Throughput ScreeningMutation
Grant awards (82)
Targeting Mutant KRAS for Cancer Therapy$771,228
R35 · FY2022 · CA · contact PI
Targeting Mutant KRAS for Cancer Therapy$839,300
R35 · FY2021 · CA · contact PI
Targeting Mutant KRAS for Cancer Therapy$873,415
R35 · FY2020 · CA · contact PI
Targeting Mutant KRAS for Cancer Therapy$481,415
R35 · FY2019 · CA · contact PI
Targeting Mutant KRAS for Cancer Therapy$415,202
R35 · FY2019 · CA · contact PI
Targeting Mutant KRAS for Cancer Therapy$924,613
R35 · FY2018 · CA · contact PI
Targeting Mutant KRAS for Cancer Therapy$924,613
R35 · FY2017 · CA · contact PI
Targeting Mutant KRAS for Cancer Therapy$960,504
R35 · FY2016 · CA · contact PI
TARGETED INTERVENTION OF BREAST ONCOGENIC PATHWAYS$301,721
R01 · FY2014 · CA · contact PI
Targeting STAT3 as a novel approach to cancer therapy$315,201
R01 · FY2013 · CA · contact PI
TARGETED INTERVENTION OF BREAST ONCOGENIC PATHWAYS$292,064
R01 · FY2013 · CA · contact PI
Targeting STAT3 as a novel approach to cancer therapy$336,674
R01 · FY2012 · CA · contact PI
TARGETED INTERVENTION OF BREAST ONCOGENIC PATHWAYS$310,370
R01 · FY2012 · CA · contact PI
Targeting Signal Transduction Pathways for Cancer Drug Discovery$1,930,691
P01 · FY2011 · CA · contact PI
Targeting STAT3 as a novel approach to cancer therapy$338,920
R01 · FY2011 · CA · contact PI
TARGETED INTERVENTION OF BREAST ONCOGENIC PATHWAYS$310,044
R01 · FY2011 · CA · contact PI
Development of Proteasome Selective Inhibitors for Cancer Therapy$293,420
P01 · FY2011 · CA · contact PI
Targeting Signal Transduction Pathways for Cancer Drug Discovery$1,992,373
P01 · FY2010 · CA · contact PI
Targeting STAT3 as a novel approach to cancer therapy$355,838
R01 · FY2010 · CA · contact PI
TARGETED INTERVENTION OF BREAST ONCOGENIC PATHWAYS$319,306
R01 · FY2010 · CA · contact PI
Development of Proteasome Selective Inhibitors for Cancer Therapy$317,179
P01 · FY2010 · CA · contact PI
Targeting Signal Transduction Pathways for Cancer Drug Discovery$88,675
P01 · FY2010 · CA · contact PI
Targeting Signal Transduction Pathways for Cancer Drug Discovery$1,950,419
P01 · FY2009 · CA · contact PI
Inhibitors of Rho function as novel cancer therapeutics$1,140,901
U19 · FY2009 · CA · contact PI
Targeting STAT3 as a novel approach to cancer therapy$348,945
R01 · FY2009 · CA · contact PI
Development of Proteasome Selective Inhibitors for Cancer Therapy$311,318
P01 · FY2009 · CA · contact PI
Biological and Pharmacological Evaluations of RhoGEF, GGTase I and Rho kinase inh$198,021
U19 · FY2009 · CA · contact PI
Targeting Signal Transduction Pathways for Cancer Drug Discovery$86,169
P01 · FY2009 · CA · contact PI
Administrative Core$49,800
U19 · FY2009 · CA · contact PI
Targeting Signal Transduction Pathways for Cancer Drug Discovery$1,888,951
P01 · FY2008 · CA · contact PI
Inhibitors of Rho function as novel cancer therapeutics$1,062,457
U19 · FY2008 · CA · contact PI
Growth Factor as Anti-angiogenesis Agents$326,968
R01 · FY2008 · CA · contact PI
Development of Proteasome Selective Inhibitors for Cancer Therapy$289,499
P01 · FY2008 · CA · contact PI
Targeting Signal Transduction Pathways for Cancer Drug Discovery$41,871
P01 · FY2008 · CA · contact PI
Targeting Signal Transduction Pathways for Cancer Drug Discovery$1,835,922
P01 · FY2007 · CA · contact PI
Inhibitors of Rho function as novel cancer therapeutics$1,104,323
U19 · FY2007 · CA · contact PI
Growth Factor as Anti-angiogenesis Agents$321,936
R01 · FY2007 · CA · contact PI
Targeted Intervention of Breast Oncogenic Pathways$286,812
R01 · FY2007 · CA · contact PI
Development of Proteasome Selective Inhibitors for Cancer Therapy$281,391
P01 · FY2007 · CA · contact PI
Inhibitors of Rho function as novel cancer therapeutics$123,140
U19 · FY2007 · CA · contact PI
Targeted Intervention of Breast Oncogenic Pathways$121,464
R01 · FY2007 · CA · contact PI
Inhibitors of Rho function as novel cancer therapeutics$1,101,207
U19 · FY2006 · CA · contact PI
Growth Factor as Anti-angiogenesis Agents$324,197
R01 · FY2006 · CA · contact PI
Targeted Intervention of Breast Oncogenic Pathways$295,378
R01 · FY2006 · CA · contact PI
Targeted Intervention of Breast Oncogenic Pathways$121,464
R01 · FY2006 · CA · contact PI
Inhibitors of Rho function as novel cancer therapeutics$94,211
U19 · FY2006 · CA · contact PI
Inhibitors of Rho function as novel cancer therapeutics$1,127,634
U19 · FY2005 · CA
Growth Factor as Anti-angiogenesis Agents$324,871
R01 · FY2005 · CA
Targeted Intervention of Breast Oncogenic Pathways$302,486
R01 · FY2005 · CA
AKT SURVIVAL PATHWAYS AND FTI INDUCED APOPTOSIS$195,750
R01 · FY2005 · CA
HIGH THROUGHPUT SCREENING AND MOLECULAR MODELING$188,431
U19 · FY2005 · CA
BIOLOGICAL AND PHARMACOLOGICAL EVALUATIONS OF RHOGEF, GGTASE I AND RHO KINASE INH$164,611
U19 · FY2005 · CA
Targeted Intervention of Breast Oncogenic Pathways$121,464
R01 · FY2005 · CA
ADMINISTRATION$37,711
U19 · FY2005 · CA
GERANYLGERANYLTRANSFERASE I INHIBITION AND CANCER THERAP$695,960
U19 · FY2004 · CA
Growth Factor as Anti-angiogenesis Agents$339,757
R01 · FY2004 · CA
Targeted Intervention of Breast Oncogenic Pathways$302,486
R01 · FY2004 · CA
AKT SURVIVAL PATHWAYS AND FTI INDUCED APOPTOSIS$195,750
R01 · FY2004 · CA
FARNESYLTRANSFERASE INHIBITORS IN CANCER THERAPY$176,608
R01 · FY2004 · CA
Targeted Intervention of Breast Oncogenic Pathways$121,464
R01 · FY2004 · CA
CANCER DRUG DISCOVERY: CELL CYCLE CONTROL TARGETS$940,402
P01 · FY2003 · CA
GERANYLGERANYLTRANSFERASE I INHIBITION AND CANCER THERAP$679,488
U19 · FY2003 · CA
Targeted Intervention of Breast Oncogenic Pathways$316,120
R01 · FY2003 · CA
AKT SURVIVAL PATHWAYS AND FTI INDUCED APOPTOSIS$195,750
R01 · FY2003 · CA
FARNESYLTRANSFERASE INHIBITORS IN CANCER THERAPY$176,608
R01 · FY2003 · CA
CANCER DRUG DISCOVERY: CELL CYCLE CONTROL TARGETS$918,099
P01 · FY2002 · CA
GERANYLGERANYLTRANSFERASE I INHIBITION AND CANCER THERAP$663,468
U19 · FY2002 · CA
ANTAGONISTS OF RECEPTOR TYROSINE KINASE ACTIVATION$197,196
P01 · FY2002 · CA
AKT SURVIVAL PATHWAYS AND FTI INDUCED APOPTOSIS$195,750
R01 · FY2002 · CA
FARNESYLTRANSFERASE INHIBITORS IN CANCER THERAPY$176,608
R01 · FY2002 · CA
PRECLINICAL EVALUATION OF MACROMOLECULAR THERAPEUTICS$0
U19 · FY2002 · CA
CANCER DRUG DISCOVERY: CELL CYCLE CONTROL TARGETS$896,446
P01 · FY2001 · CA
GERANYLGERANYLTRANSFERASE I INHIBITION AND CANCER THERAP$647,885
U19 · FY2001 · CA
ANTAGONISTS OF RECEPTOR TYROSINE KINASE ACTIVATION$197,196
P01 · FY2001 · CA
AKT SURVIVAL PATHWAYS AND FTI INDUCED APOPTOSIS$195,750
R01 · FY2001 · CA
FARNESYLTRANSFERASE INHIBITORS IN CANCER THERAPY$178,588
R01 · FY2001 · CA
PRECLINICAL EVALUATION OF MACROMOLECULAR THERAPEUTICS$0
U19 · FY2001 · CA
CANCER DRUG DISCOVERY: CELL CYCLE CONTROL TARGETS$875,425
P01 · FY2000 · CA
GERANYLGERANYLTRANSFERASE I INHIBITION &CANCER THERAPY$473,333
U19 · FY2000 · CA
FARNESYLTRANSFERASE INHIBITORS IN CANCER THERAPY$195,750
R01 · FY2000 · CA
ANTAGONISTS OF RECEPTOR TYROSINE KINASE ACTIVATION$113,675
P01 · FY2000 · CA
PRECLINICAL EVALUATION OF MACROMOLECULAR THERAPEUTICS$0
U19 · FY2000 · CA